Avectas is a cell engineering technology business focused on improving the cost, manufacturing and patient outcomes for the next generation of cellular therapies. Avectas is developing a unique cell engineering platform, SOLUPORE™, to enable the ex-vivo manufacture of gene modified cell therapy products. SOLUPORE™ is a patented, non-viral, cell engineering technology that permeabilizes the target cell membrane and allows efficient transfer of cargo into cells whilst retaining very high levels of cell viability and functionality. The SOLUPORE™ technology is designed for use with mRNA, DNA, and proteins, including gene editing tools such as CRISPR. SOLUPORE™ achieves excellent engineering efficiencies for delivery of these payloads to primary T cells and NK cells for immuno-oncology and gene editing applications. Avectas is currently developing the clinical (cGMP) technology embodiment while enhancing its dataset, implementing its commercialization strategy and building out the team.